A study shows that many cancer drugs given accelerated approval fail to show benefits within five years.
The US Food and Drug Administration’s accelerated approval programme is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives?
The programme was created in 1992 to speed up access to HIV drugs. Today, 85 percent of accelerated approvals go to cancer drugs. The new study found that between 2013 and 2017, there were 46 cancer drugs granted accelerated approval. Of those, 63 percent were converted to regular approval even though only 43 percent demonstrated a clinical benefit in confirmatory trials.
Turkey Middle East Africa Europe China Us Germany News Breaking News Context Explainer Opinion Economy Business Trends Humans Globalisation Russia Rt Trt Trt World Journalism Human Interest
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
'Study drugs' set the stage for other drug use and mental health declineTaking 'study drugs' like Adderall without a diagnosis is not only dangerous in itself, but can lead to other drug use and a decline in mental health, according to new research.
Read more »
Taking 'Study Drugs' Like Adderall Could Be Gateway to More Drug AbuseCollege students who use drugs like Adderall to help them focus on their studies may be setting themselves up for trouble.
Read more »
Even among the insured, weight loss drugs are rarely prescribed, study suggestsSara G. Miller is the health editor for NBC News, Health & Medical Unit.
Read more »
Lenz Therapeutics' Eye Disease Drugs Meet Main Goal Of Late-stage StudyLenz Therapeutics said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study, sending its shares up nearly 23% before the...
Read more »
College Students Beware: Taking “Study Drugs” Can Have Serious ConsequencesScience, Space and Technology News 2024
Read more »
New study paves the way for precision drugs to treat blood cancersThe Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses.
Read more »